Stock 600566 HUBEI JUMPCAN PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Hubei Jumpcan Pharmaceutical Co., Ltd.

Equities

600566

CNE0000018X6

End-of-day quote Shanghai S.E.
Other stock markets
 03:30:00 26/04/2024 am IST 		5-day change 1st Jan Change
40.15 CNY -0.35% Intraday chart for Hubei Jumpcan Pharmaceutical Co., Ltd. -8.67% +27.74%
19/04 Hubei Jumpcan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
09/04 Hubei Jumpcan Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Hubei Jumpcan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Hubei Jumpcan Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Tranche Update on Hubei Jumpcan Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on July 4, 2023.
CI
Tranche Update on Hubei Jumpcan Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on July 4, 2023.
CI
Jumpcan Pharma Registers Two New Drugs
MT
Hubei Jumpcan Pharma’s Q3 Profit Jumps 4.8%, Revenue Falls 6%
MT
Hubei Jumpcan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Nanjing Zenshine Pharmaceuticals Co., Ltd. announced that it has received CNY 100 million in funding from Hubei Jumpcan Pharmaceutical Co., Ltd., Kunlun Capital, Zhejiang Saizhi Bole Equity Investment Management Co., Ltd, Zhongshan Zhonghui Investment Group Co.,ltd.
CI
Tranche Update on Hubei Jumpcan Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on July 4, 2023.
CI
Nanjing Zenshine Pharmaceuticals Co., Ltd. announced that it expects to receive CNY 60 million in funding from Hubei Jumpcan Pharmaceutical Co., Ltd.
CI
Hubei Jumpcan Pharma Registers Oral Solution to Treat ADHD
MT
Hubei Jumpcan Pharma Logs Double-Digit Earnings Growth in H1 on Strong Sales, Reduced Costs; Shares Jump 5%
MT
Hubei Jumpcan Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Hubei Jumpcan Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 40 million worth of its shares.
CI
Hubei Jumpcan Pharmaceutical Co., Ltd. authorizes a Buyback Plan.
CI
Hubei Jumpcan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Hubei Jumpcan Pharma to Apply For Up to 2 Billion Yuan Loan in 2023
MT
China's Weibo ups stake in Inmyshow Digital with $315 million acquisition
RE
Hubei Jumpcan Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Rating Agency Ends Rating Hubei Jumpcan Pharmaceutical's Bonds
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 600566 Stock
  4. News Hubei Jumpcan Pharmaceutical Co., Ltd.